These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 17319456

  • 1. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI.
    Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
    [Abstract] [Full Text] [Related]

  • 2. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 3. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N, White H.
    Vasc Health Risk Manag; 2007 Jun; 3(4):425-30. PubMed ID: 17969373
    [Abstract] [Full Text] [Related]

  • 4. ACE inhibitors in heart failure: what more do we need to know?
    Demers C, Mody A, Teo KK, McKelvie RS.
    Am J Cardiovasc Drugs; 2005 Jun; 5(6):351-9. PubMed ID: 16259523
    [Abstract] [Full Text] [Related]

  • 5. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM.
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [Abstract] [Full Text] [Related]

  • 6. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA.
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [Abstract] [Full Text] [Related]

  • 7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 8. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Feb 21; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 9. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

  • 10. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R.
    Am Heart J; 2000 Nov 28; 140(5):727-50. PubMed ID: 11054617
    [Abstract] [Full Text] [Related]

  • 11. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
    Croom KF, Keating GM.
    Am J Cardiovasc Drugs; 2004 Nov 28; 4(6):395-404. PubMed ID: 15554725
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 28; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA.
    Heart Rhythm; 2007 Mar 28; 4(3):308-13. PubMed ID: 17341394
    [Abstract] [Full Text] [Related]

  • 14. Valsartan after myocardial infarction.
    Güleç S.
    Anadolu Kardiyol Derg; 2014 Dec 28; 14 Suppl 2():S9-13. PubMed ID: 25604205
    [Abstract] [Full Text] [Related]

  • 15. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
    Maggioni AP, Fabbri G.
    Expert Opin Pharmacother; 2005 Mar 28; 6(3):507-12. PubMed ID: 15794740
    [Abstract] [Full Text] [Related]

  • 16. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J, Krum H.
    Pharmacol Res; 2002 Sep 28; 46(3):203-12. PubMed ID: 12220962
    [Abstract] [Full Text] [Related]

  • 17. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 28; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

  • 18. Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
    Miura T, Yuda S.
    Circ J; 2009 May 28; 73(5):820-1. PubMed ID: 19390158
    [No Abstract] [Full Text] [Related]

  • 19. Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction.
    Ovricenco E, Sinescu C, Dinescu S.
    J Med Life; 2008 May 28; 1(3):323-33. PubMed ID: 20108509
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 28; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.